Significance, Specificity, and Ultrastructural Localization of HMB-45 Antigen in Pigmented Ocular Tumors

Steuhl, Klaus‐Peter; Rohrbach, Jens Martin; Knorr, M.; Thiel, Holger

doi:10.1016/s0161-6420(93)31668-4

Cited by 50 publications

(51 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…tyrosinase and TRP-I in 32 primary ux-eal melanomas and four metastases. Although expression of gplOO in uveal melanomas was studied some time ago (Van der Pol et al 1987: Ringens et al 1989: Steuhl et al 1993. knowledge of expression of the other three proteins is lacking.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma

Vries

Trancikova²,

Ruiter³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary In the treatment of cutaneous melanoma, provisional therapeutic strategies have been designed to combat tumour load using T cells that are sensitized with peptides derived from melanoma autoantigens, such as glycoprotein 100 (gp100), melanoma antigen recognized by T cells 1 (MART-1 or MelanA), tyrosinase and tyrosinase-related protein 1 (TRP-1). We recently found that gpl 00, MART-1 and tyrosinase are heterogeneously expressed in human cutaneous melanoma (De Vries et al (1997) Monoclonal antibodies against gplOO has-e successfullv been implemented in diagnostic pathology of cutaneous and uveal melanoma (Carrel and Rimoldi. 1993: Ruiter andBrocker. 1993).Antibodies against three other melanoma antigens. MART-I (Chen et al. 1996). tyrosinase (Chen et al. 1995) and TRP-1 (Chen et al.1995) have recentlx been described. The recent discoxerx that peptides derived from gplOO (Bakker et al. 1994 (Tobal et al. 1993: Foss et al. 1995.For both those who design immunotherapy protocols and those w ho perform RT-PCRs based on the presence of melanomaspecific mRNA in patients blood, it is important to knoxx the content of these antigens in primary tumours. Recentlv. we studied the presence of gp 100. MART-1 and tyrosinase in cutaneous melanocvtic lesions. We found that approximately 20% of the

show abstract

Section: Discussionmentioning

confidence: 99%

“…such as gplOO (Van der Pol et al 1987: Ringens et al 1989: Steuhl et al 1993). S100 (Kan-Mitchel et al 1990) and high molecular weigaht melanoma-associated antigen (HMW-MAA) (Natali et al 1989) also occured in uveal melanoma cells.…”

mentioning

confidence: 99%

High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma

Vries

Trancikova²,

Ruiter³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…[16][17][18][19][20]27,28 With the application of monoclonal antibodies against the nuclear proliferation protein Ki-67, which is more sensitive than counting mitotic figures for determining cellular proliferative activity (ie, identifying nuclei in late G1, S, M, and G2 phases of the cell cycle), the ability to diagnose cutaneous benign and malignant disorders has been further improved. [5][6][7][8][9][10][11][12][13] This probe, however, has yet to be systematically used in studies of common conjunctival melanocytic lesions.…”

Section: Commentmentioning

confidence: 99%

Immunohistochemical Studies of Conjunctival Nevi and Melanomas

Jakobiec

Bhat²,

Colby³

2010

Arch Ophthalmol

View full text Add to dashboard Cite

To evaluate the role of immunohistochemical methods in the diagnosis of benign and malignant conjunctival melanocytic proliferations.Design: Retrospective immunohistopathologic study.Methods: Paraffin-embedded tissue sections from 20 conjunctival nevi and 15 invasive melanomas were immunoreacted with antibodies against cellular antigens S-100 protein, MART-1, HMB-45, CD-45, and Ki-67 nuclear proliferation protein.Results: All nevi immunostained moderately to strongly for S-100 protein and MART-1. Results for HMB-45 were negative in the middle and lower subepithelial portions of 18 of 20 lesions; it was usually only weakly positive within the superficial junctional zone. Only 1 melanoma did not stain positively for S-100; MART-1 and HMB-45 were positive in all lesions at some level of intensity. Ki-67 positivity was restricted to the junctional zone of nevi and was diffuse in melanomas. The mean Ki-67 proliferation indices were 1.89% for the nevi and 17.3% for the melanomas. CD-45 can help to highlight lymphocytes that immunostain with Ki-67. Melanomas in situ and atypical primary acquired melanoses had more than twice the Ki-67 proliferation counts of intraepithelial junctional nevocytes (P Ͻ .001) and more intense HMB-45 cytoplasmic staining than junctional zone nevocytes.Conclusions: S-100 and MART-1 were not useful in separating benign from malignant lesions. Results for nevus cells beneath the junctional zone were overwhelmingly negative for HMB-45 and Ki-67. Two nevi and all melanomatous nodules were positive for HMB-45 (PϽ.001). A higher Ki-67 proliferation index convincingly separated melanomas from nevi (P Ͻ .001). Immunostaining for HMB-45 and Ki-67 are valuable adjuncts to careful histopathologic evaluation in assessing benign and malignant conjunctival melanocytic tumors.

show abstract

“…The primary mouse MAbs HMB-45 (lot 0024b; DAKO A/S, Copenhagen, Denmark; diluted 1 : 200) to immature melanosomes that labels more than 90% of primary and metastatic uveal melanomas (30)(31)(32), MAb CY-90 (lot 49F-4815; Sigma Chemical Co.; 1 : 3000) to cytokeratin 18 that is expressed by adenocarcinomas, but can also be found in a minority of cells in uveal melanomas (26), MAb Vim 3B4 (lot 114544324-01; BoehringerMannheim GmbH, Mannheim, Germany; diluted 1 : 50) to vimentin that labels uveal melanomas (26) but may also label cells in some carcinomas, and MAb E29 (lot 078; DAKO; diluted 1 : 25) to epithelial membrane antigen produced by adenocarcinomas but not by melanomas (33) were commercially obtained. A tumor was accepted as a melanoma if it reacted for HMB-45, vimentin, or both, but not for cytokeratin 18 and epithelial membrane antigen, and as a carcinoma when the antigenic profile was the opposite.…”

Section: Follow-up Data and Histopathology Of Metastasesmentioning

confidence: 99%

Microvascular Loops and Networks as Prognostic Indicators in Choroidal and Ciliary Body Melanomas

Mäkitie¹,

Summanen²,

Tarkkanen³

et al. 1999

JNCI Journal of the National Cancer Institute

143

View full text Add to dashboard Cite

Background: Malignant melanoma of the ciliary body and choroid of the eye is a tumor that disseminates frequently, and 50% of the diagnosed patients die within 10 years. We investigated the hypothesis that, by histopathologic analysis of the arrangement of microvessels (i.e., small blood vessels) in loops and networks, we might be able to differentiate better those patients with a favorable prognosis from those with a poor prognosis. Methods: We conducted a populationbased, retrospective cohort study of melanoma-specific and all-cause mortality for 167 consecutive patients who had an eye surgically removed because of malignant choroidal or ciliary body melanoma during the period from 1972 through 1981. Microvascular loops and networks were evaluated independently by two pathologists who were unaware of patient outcome.

show abstract

Significance, Specificity, and Ultrastructural Localization of HMB-45 Antigen in Pigmented Ocular Tumors

Cited by 50 publications

References 22 publications

High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma

High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma

Immunohistochemical Studies of Conjunctival Nevi and Melanomas

Microvascular Loops and Networks as Prognostic Indicators in Choroidal and Ciliary Body Melanomas

Contact Info

Product

Resources

About